{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T08:14:06Z","timestamp":1763367246453},"reference-count":45,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","progcardvascdis.com","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Progress in Cardiovascular Diseases"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1016\/j.pcad.2017.08.006","type":"journal-article","created":{"date-parts":[[2017,8,25]],"date-time":"2017-08-25T18:20:11Z","timestamp":1503685211000},"page":"187-197","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Pharmacologic Therapy for Heart Failure With Reduced Ejection Fraction: Closing the Gap Between Clinical Guidelines and Practice"],"prefix":"10.1016","volume":"60","author":[{"given":"J. Barr","family":"Biglane","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miriam F.","family":"Becnel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hector O.","family":"Ventura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Selim R.","family":"Krim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.pcad.2017.08.006_bb0005","doi-asserted-by":"crossref","first-page":"e146","DOI":"10.1161\/CIR.0000000000000485","article-title":"Heart disease and stroke statistics-2017 update: a report from the American Heart Association","volume":"135","author":"Benjamin","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.pcad.2017.08.006_bb0010","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1016\/j.jacc.2013.11.053","article-title":"The global health and economic burden of hospitalizations for heart failure. lessons learned from hospitalized heart failure registries","volume":"63","author":"Ambrosy","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2017.08.006_bb0015","series-title":"Improving Care for Patients With Acute Heart Failure","author":"Cowie","year":"2014"},{"issue":"13","key":"10.1016\/j.pcad.2017.08.006_bb0020","doi-asserted-by":"crossref","first-page":"e282","DOI":"10.1161\/CIR.0000000000000435","volume":"134","author":"Yancy","year":"2016","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.pcad.2017.08.006_bb0025","doi-asserted-by":"crossref","first-page":"e137","DOI":"10.1161\/CIR.0000000000000509","volume":"136","author":"Yancy","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.pcad.2017.08.006_bb0030","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/S0140-6736(10)61198-1","article-title":"Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study","volume":"376","author":"Swedberg","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.pcad.2017.08.006_bb0035","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2017.08.006_bb0040","first-page":"167","article-title":"ABC of heart failure","volume":"320","author":"Jackson","year":"2000","journal-title":"Pathophysiology"},{"issue":"2","key":"10.1016\/j.pcad.2017.08.006_bb0045","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1161\/01.CIR.85.2.790","article-title":"Adrenergic effects on the biology of the adult mammalian cardiocyte","volume":"85","author":"Mann","year":"1992","journal-title":"Circulation"},{"key":"10.1016\/j.pcad.2017.08.006_bb0050","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJM198606123142404","article-title":"Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study","volume":"314","author":"Cohn","year":"1986","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2017.08.006_bb0055","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1056\/NEJM199108013250502","article-title":"A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure","volume":"325","author":"Cohn","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2017.08.006_bb0060","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1056\/NEJM198706043162301","volume":"316","year":"1987","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2017.08.006_bb0065","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1056\/NEJM199108013250501","volume":"325","year":"1991","journal-title":"N Engl J Med"},{"issue":"23","key":"10.1016\/j.pcad.2017.08.006_bb0070","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1056\/NEJMoa010713","article-title":"Valsartan heart failure trial investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure","volume":"345","author":"Cohn","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2017.08.006_bb0075","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/S0140-6736(03)14284-5","article-title":"Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting enzyme inhibitors: the CHARM-alternative trial","volume":"362","author":"Granger","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.pcad.2017.08.006_bb0080","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1161\/01.CIR.90.4.1765","article-title":"A randomized trial of beta-blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study (CIBIS)","volume":"90","author":"CIBIS Investigators and Committees","year":"1994","journal-title":"Circulation"},{"key":"10.1016\/j.pcad.2017.08.006_bb0085","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1056\/NEJM199605233342101","article-title":"The effect of carvedilol on morbidity and mortality in patients with chronic heart failure: U.S. Carvedilol Heart Failure Study Group","volume":"334","author":"Packer","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2017.08.006_bb0090","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1056\/NEJM200105313442201","article-title":"Effect of carvedilol on survival in severe chronic heart failure","volume":"344","author":"Packer","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2017.08.006_bb0095","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1016\/S0140-6736(99)04440-2","volume":"353","year":"1999","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.pcad.2017.08.006_bb0100","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2017.08.006_bb0105","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1009492","article-title":"Eplerenone in patients with systolic heart failure and mild symptoms","volume":"364","author":"Zannad","year":"2011","journal-title":"N Engl J Med"},{"issue":"20","key":"10.1016\/j.pcad.2017.08.006_bb0110","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1056\/NEJMoa042934","article-title":"Combination of isosorbide dinitrate and hydralazine in blacks with heart failure","volume":"351","author":"Taylor","year":"2004","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.pcad.2017.08.006_bb0115","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/0002-9343(81)90755-5","article-title":"Effect of diuresis on the performance of the failing left ventricle in man","volume":"70","author":"Wilson","year":"1981","journal-title":"Am J Med"},{"issue":"3","key":"10.1016\/j.pcad.2017.08.006_bb0120","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.ahj.2014.12.009","article-title":"A reappraisal of loop diuretic choice in heart failure patients","volume":"169","author":"Buggey","year":"2015","journal-title":"Am Heart J"},{"issue":"7","key":"10.1016\/j.pcad.2017.08.006_bb0125","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/S0002-9343(01)00903-2","article-title":"Open-label randomized trial of torsemide compared with furosemide therapy for patients with heart failure","volume":"111","author":"Murray","year":"2001","journal-title":"Am J Med"},{"issue":"1","key":"10.1016\/j.pcad.2017.08.006_bb0130","doi-asserted-by":"crossref","first-page":"42","DOI":"10.15420\/ecr.2015.10.01.42","article-title":"Diuretic therapy in heart failure\u2014current approaches","volume":"10","author":"Casu","year":"2015","journal-title":"Eur Cardiol Rev"},{"issue":"9","key":"10.1016\/j.pcad.2017.08.006_bb0135","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1056\/NEJMoa1005419","article-title":"Diuretic strategies in patients with acute decompensated heart failure","volume":"364","author":"Felker","year":"2011","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.pcad.2017.08.006_bb0140","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1016\/j.amjcard.2010.01.355","article-title":"Continuous versus bolus dosing of furosemide for patients hospitalized for heart failure","volume":"105","author":"Allen","year":"2010","journal-title":"Am J Cardiol"},{"issue":"5","key":"10.1016\/j.pcad.2017.08.006_bb0145","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1097\/MAJ.0b013e318176b94d","article-title":"Digoxin: current use and approach to toxicity","volume":"336","author":"Vivo","year":"2008","journal-title":"Am J Med Sci"},{"key":"10.1016\/j.pcad.2017.08.006_bb0150","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1001\/jama.1988.03720040031022","article-title":"Comparative effects of therapy with captopril and digoxin in patients with mild to moderate heart failure","volume":"259","author":"The Captopril-Digoxin Multicenter Research Group","year":"1988","journal-title":"JAMA"},{"key":"10.1016\/j.pcad.2017.08.006_bb0155","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1056\/NEJM199702203360801","article-title":"The effect of digoxin on mortality and morbidity in patients with heart failure","volume":"336","author":"The Digitalis Investigation Group","year":"1997","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.pcad.2017.08.006_bb0160","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1056\/NEJM199307013290101","article-title":"Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting-enzyme inhibitors. RADIANCE Study","volume":"329","author":"Packer","year":"1993","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.pcad.2017.08.006_bb0165","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/0735-1097(93)90403-N","article-title":"Randomized study assessing the effect of digoxin withdrawal in patients with mild to moderate chronic congestive heart failure: results of the PROVED trial. PROVED Investigative Group","volume":"22","author":"Uretsky","year":"1993","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.pcad.2017.08.006_bb0170","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jacc.2005.03.051","article-title":"In-hospital mortality in patients with acute decompensated heart failure requiring intravenous vasoactive medications: an analysis from the Acute Decompensated Heart Failure National Registry (ADHERE)","volume":"46","author":"Abraham","year":"2005","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"10.1016\/j.pcad.2017.08.006_bb0175","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1001\/jama.287.12.1541","article-title":"Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial","volume":"287","author":"Cuffe","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.pcad.2017.08.006_bb0180","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1023\/B:CARD.0000025756.32499.6f","article-title":"The benefits of early combination treatment of carvedilol and an ACEinhibitor in mild heart failure and left ventricular systolic dysfunction. The carvedilol and ACE-inhibitor remodelling mild heart failure evaluation trial (CARMEN)","volume":"18","author":"Remme","year":"2004","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.pcad.2017.08.006_bb0185","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1016\/j.jacc.2004.05.087","article-title":"Impact of initiating carvedilol before angiotensin converting enzyme inhibitor therapy on cardiac function in newly diagnosed heart failure","volume":"44","author":"Sliwa","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2017.08.006_bb0190","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1016\/j.jacc.2003.12.040","article-title":"Pre-discharge initiation of carvedilol in patients hospitalized for decompensated heart failure: results of the IMPACT-HF (initiation management predischarge process for assessment of carvedilol therapy in heart failure) trial","volume":"43","author":"Gattis","year":"2004","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"10.1016\/j.pcad.2017.08.006_bb0195","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.jchf.2015.09.002","article-title":"Heart rate or beta-blocker dose? Association with outcomes in ambulatory heart failure patients with systolic dysfunction: results from the HF-ACTION trial","volume":"4","author":"Fiuzat","year":"2016","journal-title":"JACC Heart Fail"},{"issue":"9","key":"10.1016\/j.pcad.2017.08.006_bb0200","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/j.jacc.2013.11.031","article-title":"Current evidence on treatment of patients with chronic systolic heart failure and renal insufficiency: practical considerations from published data","volume":"63","author":"Damman","year":"2014","journal-title":"J Am Coll Cardiol"},{"issue":"34","key":"10.1016\/j.pcad.2017.08.006_bb0205","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1093\/eurheartj\/ehv268","article-title":"Association between renin-angiotensin system antagonist use and mortality in heart failure with severe renal insufficiency: a prospective propensity score-matched cohort study","volume":"36","author":"Edner","year":"2015","journal-title":"Eur Heart J"},{"issue":"7","key":"10.1016\/j.pcad.2017.08.006_bb0210","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1093\/eurjhf\/hft028","article-title":"Heart failure in elderly patients: distinctive features and unresolved issues","volume":"15","author":"Lazzarini","year":"2013","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.pcad.2017.08.006_bb0215","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1093\/eurheartj\/ehi115","article-title":"Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS)","volume":"26","author":"Flather","year":"2005","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pcad.2017.08.006_bb0220","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1093\/eurjhf\/hfr020","article-title":"Titration to target dose of bisoprolol vs. carvedilol in elderly patients with heart failure: the CIBIS-ELD trial","volume":"13","author":"Dungen","year":"2011","journal-title":"Eur J Heart Fail"},{"issue":"6","key":"10.1016\/j.pcad.2017.08.006_bb0225","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1001\/jamacardio.2016.1724","article-title":"Potential mortality reduction with optimal implementation of angiotensin receptor neprilysin inhibitor therapy in heart failure","volume":"1","author":"Fonarow","year":"2016","journal-title":"JAMA Cardiol"}],"container-title":["Progress in Cardiovascular Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0033062017301159?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0033062017301159?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,28]],"date-time":"2018-08-28T09:21:03Z","timestamp":1535448063000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0033062017301159"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9]]},"references-count":45,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,9]]}},"alternative-id":["S0033062017301159"],"URL":"https:\/\/doi.org\/10.1016\/j.pcad.2017.08.006","relation":{},"ISSN":["0033-0620"],"issn-type":[{"value":"0033-0620","type":"print"}],"subject":[],"published":{"date-parts":[[2017,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacologic Therapy for Heart Failure With Reduced Ejection Fraction: Closing the Gap Between Clinical Guidelines and Practice","name":"articletitle","label":"Article Title"},{"value":"Progress in Cardiovascular Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pcad.2017.08.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}